Home > Healthcare > Biotechnology > Biotechnology R&D > genetic testing market
Get a free sample of Genetic Testing Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Genetic Testing Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The significance of genetic testing is increasing with the development of innovations and new technologies. The availability of efficient and highly sensitive DNA sequencing methods for prenatal genetic testing offers new approaches for initial screening during pregnancy. These methods allow the detection of small amounts of fetal DNA that naturally circulate in the mother's blood during pregnancy.
The kits & reagents segment dominated the market, generating a revenue of USD 12.1 billion in 2023. This segment includes next-generation sequencing (NGS) kits, which provide a high-throughput method for sequencing entire genomes or specific regions, facilitating comprehensive genetic analysis for both research and clinical diagnostics.
The global genetic testing industry was valued at USD 18.6 billion in 2023 and is projected to grow at a CAGR of 12.3% from 2024 to 2032, driven by advancements in genomics, including high-throughput sequencing technologies and enhanced bioinformatics tools.
North America secured a substantial market share of 46.3% in 2023 and is expected to dominate throughout the forecast period. The regions growth is supported by the presence of major market players and leading research institutions focused on genetic research, creating a conducive environment for market expansion.
Key players in the genetic testing industry include 23 and ME, Inc., Abbott Laboratories, Ambry Genetics, Ancestry DNA, bioMerieux SA, BGI Genomics, Illumina, Inc., Invitae Corporation, Luminex Corporation, Myriad Genetics, Inc., Natera, Inc., QIAGEN N.V., Quest Diagnostics, and Siemens Healthineers AG.